Nectar Lifesciences Share Price

Nectar Lifesciences Limited is an India-based pharmaceutical company. The Company's business areas include active pharmaceutical ingredients (APIs) and intermediates, formulations/finished dosage formulations (FDF), menthol and mint derivatives, and empty hard gelatin capsules. The Company is engaged in the manufacturing of oral and sterile cephalosporin products. Its oral cephalosporins include cefixime, cefurozime axetil crystalline, cefuroxime axetil amorphous, cedpodoxime proxetil, cefprozil and cefdinir. Its sterile cephalosporins include cefotaxime sodium, ceftriaxone sodium, cefuroxime sodium, cefazolin sodium, ceftazidime pentahydrate and cefepime arginine. Its capacities include cefixime, cefuroxime axetil amorphous, cefuroxime axetil crystalline, cefotaxime sodium and ceftriaxone sodium. The Company offers contract manufacturing capabilities for solid dosage forms, such as tablets, capsules, dry powder oral suspension and granules and injectable for cephalosporins.As of 26 May 2026, Nectar Lifesciences share price is ₹12.15. The stock opened at ₹12.06, compared to its previous close of ₹12.06. During today's trading session, Nectar Lifesciences share price moved in the range of ₹12.03 to ₹12.61, with an average price of ₹12.32 for the day. Looking at its last 52-week, the stock has touched a low of ₹12.03 and a high of ₹12.61. On the performance front, Nectar Lifesciences share price has declined by 20.01% over the last six months and is down 48.76% on a year-on-year basis.

The market capitalization of Nectar Lifesciences is ₹235 Crs, with a P/E ratio of -0.7 and a dividend yield of 0.00%.